Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures

被引：9

作者：

Thoueille, Paul ^{[1
,2
]}

Cavassini, Matthias ^{[2
,3
]}

Guidi, Monia ^{[1
,2
,4
,5
]}

Buclin, Thierry ^{[1
,2
]}

Girardin, Francois R. ^{[1
,2
]}

Decosterd, Laurent A. ^{[1
,2
]}

Marzolini, Catia ^{[1
,6
,7
,8
,9
]}

机构：

[1] Lausanne Univ Hosp, Dept Lab Med & Pathol, Serv & Lab Clin Pharmacol, Lausanne, Switzerland

[2] Univ Lausanne, Lausanne, Switzerland

[3] Lausanne Univ Hosp, Dept Med, Serv Infect Dis, Lausanne, Switzerland

[4] Lausanne Univ Hosp, Ctr Res & Innovat Clin Pharmaceut Sci, Lausanne, Switzerland

[5] Univ Lausanne, Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Geneva, Switzerland

[6] Univ Basel, Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Basel, Switzerland

[7] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, England

[8] Lausanne Univ Hosp, Dept Lab Med & Pathol, Serv & Lab Clin Pharmacol, Rue Bugnon 17, Lausanne, Switzerland

[9] Univ Lausanne, Rue Bugnon 17, Lausanne, Switzerland

来源：

OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 02期

基金：

瑞士国家科学基金会;

关键词：

cabotegravir; guidance; long-acting; rilpivirine; TDM; ADULTS;

D O I：

10.1093/ofid/ofae023

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The interpretation of long-acting cabotegravir and rilpivirine concentrations is complicated by the lack of consensus on the threshold to consider. Building on real-world therapeutic drug monitoring data and documented virologic failures, this article provides a reappraisal of the existing thresholds and guidance for the interpretation of cabotegravir and rilpivirine concentrations. There is no established threshold for the interpretation of long-acting cabotegravir/rilpivirine concentrations. Building on real-world TDM data and documented virologic failures, this article provides a reappraisal of the existing thresholds, and guidance for the interpretation of cabotegravir and rilpivirine concentrations.

引用

页数：4

共 50 条

[41] Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data
Munday, Jennifer
Greene, Mallik
Chang, Eunice
Hartry, Ann
Yan, Tingjian
Broder, Michael S.
CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) : 1231 - 1239
[42] Use of Long-Acting Muscarinic Antagonists and Biologic Therapy as Add-On Treatment for Asthma: Real-World Data Analysis Using Insurance Claims from 2012-2017
Chen, H.
Ding, Y.
Spain, C.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[43] Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A
Olivieri, Martin
Simpson, Mindy
Yan, Songkai
Fedorovsky, Johanna
Zhang, Xiang
Tomic, Radovan
Pinachyan, Karen
Mancuso, Maria Elisa
CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (07) : 1133 - 1139
[44] COST-EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS VERSUS LONG-ACTING INSULINS IN TYPE 2 DIABETES FROM THE HEALTHCARE SECTOR PERSPECTIVE: A MODEL-BASED ANALYSIS USING REAL-WORLD DATA
Yao, W. Y.
Yang, C. T.
Ou, H. T.
Kuo, S.
VALUE IN HEALTH, 2022, 25 (12) : S60 - S61
[45] Cost-effectiveness analysis of genotype screening and therapeutic drug monitoring in patients with inflammatory bowel disease treated with azathioprine therapy: a Chinese healthcare perspective using real-world data
Zeng, Dayong
Huang, Xiaoting
Lin, Shen
Lin, Rongfang
Weng, Xiuhua
Huang, Pinfang
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (14)
[46] Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data
Yang, Chun-Ting
Yao, Wen-Yu
Ou, Huang-Tz
Kuo, Shihchen
DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 198
[47] Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry
Ueberall, Michael A.
Silvan, Carlos Vila
Essner, Ute
Mueller-Schwefe, Gerhard H. H.
PAIN MEDICINE, 2022, 23 (04) : 745 - 760
[48] THERAPEUTIC DRUG MONITORING (TDM) OF INFLIXIMAB IS ASSOCIATED WITH LOWER BIOLOGIC SWITCH & EXPENDITURES COMPARED TO NO-TDM COHORT OF IBD PATIENTS BASED ON 12 TO 48-MONTH REAL-WORLD OUTCOMES FROM A US COMMUNITY GI PRACTICE
Shim, A.
Young, K.
Sabban, A.
Eisdorfer, R.
Rosenberg, S.
VALUE IN HEALTH, 2024, 27 (06) : S389 - S389
[49] COMPARISON OF LONG-TERM OUTCOMES, MEASURED AS 36-MONTH REAL-WORLD IBD HOSPITALIZATIONS, SURGERIES, AND EXPENDITURES, BETWEEN INFLIXIMAB DOSE OPTIMIZED USING THERAPEUTIC DRUG MONITORING (TDM) VS NO TDM CONTROL IN A US COMMUNITY GASTROENTEROLOGY PRACTICE
Shim, Andrew
Han, Patricia Aragon
Young, Kendra
Sabban, Amit
Eisdorfer, Robert M.
Rosenberg, Shahar
GASTROENTEROLOGY, 2024, 166 (05) : S819 - S819
[50] COMPARING REAL-WORLD OUTCOMES, MEASURED AS 12 AND 24-MONTH IBD-RELATED SURGERIES, BETWEEN INFLIXIMAB DOSE OPTIMIZED PATIENTS USING THERAPEUTIC DRUG MONITORING (TDM) VS AN UNOPTIMIZED CONTROL GROUP, IN A LARGE US COMMUNITY-BASED GASTROENTEROLOGY PRACTICES
Shim, Andrew
Han, Patita
Young, Kendra
St Jacque, Samantha
Sabban, Amit
Eisdorfer, Robert
Rosenberg, Shahar
INFLAMMATORY BOWEL DISEASES, 2024, 30 : S83 - S84

← 1 2 3 4 5 →